Article

Gender Differences in the Long-Chain Polyunsaturated Fatty Acid Status: Systematic Review of 51 Publications

Department of Pediatrics, University of Pécs, Pécs, Hungary.
Annals of Nutrition and Metabolism (Impact Factor: 2.62). 01/2013; 62(2):98-112. DOI: 10.1159/000345599
Source: PubMed

ABSTRACT

Background/aims:
Sex hormones may influence the activity of enzymes which are involved in the synthesis of long-chain polyunsaturated fatty acids. The objective of this review was to assess the role of gender in determining the fatty acid composition of human samples, like plasma and erythrocyte membrane lipids, and adipose tissue.

Methods:
The method included a structured search strategy on MEDLINE, Scopus and the Cochrane databases, with formal inclusion/exclusion criteria, data extraction procedure and meta-analysis.

Results:
We evaluated 51 publications, dated from 1975 to 2011. Meta-analysis showed significantly lower values of both arachidonic acid (AA) and docosahexaenoic acid (DHA) in total plasma lipids (32 and 33 studies) and in plasma phospholipids (PL; 21 and 23 studies) in men than in women. Primary analysis of the phospholipid fraction showed the mean difference in AA to be 0.42% weight/weight (95% CI: 0.18-0.65, n = 7,769) and in DHA 0.37% weight/weight (95% CI: 0.24-0.51, n = 8,541), while there was no gender difference in the values of linoleic acid and α-linolenic acid.

Conclusions:
This systematic review based on 51 publications showed significantly lower contribution of AA and DHA to plasma total lipids and plasma PL in men than in women. Gender distribution should be regarded as a significant potential confounding factor in every study assessing data on fatty acid composition.

Download full-text

Full-text

Available from: Szimonetta Lohner, Apr 13, 2015
  • Source
    • ". Scatter plot of the changes of DHA versus the changes of ADAS-cog during 6 months of 3 FA supplementation, adjusted for baseline ADAS-cog scores, baseline weight, and gender (B = –0.834, p = 0.016). of EPA and DHA in relation to gender in humans and rats [7] [8] [9]. The gender differences have been attributed to sex hormones affecting turnover of these FAs [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: ω3 fatty acids (ω3 FAs) may slow the rate of decline in cognitive performance in mild forms of cognitive impairment and Alzheimer's disease (AD). However, the relationship between changes of plasma ω3 FA levels and cognitive performance, as well as effects of gender, are poorly known. Objective: To study the effect of 6-month administration of DHA-rich ω3 FA supplementation on plasma FA profiles in patients with mild to moderate AD in relation to cognitive performance and gender. This investigation is part of the OmegAD Study. Methods: 174 AD patients (74 ± 9 years) were randomized to a daily intake of 2.3 g ω3 FA or placebo for 6 months; subsequently all received the ω3 FA preparation for the next 6 months. Baseline as well as changes in plasma levels of the main ω3 FAs in 165 patients, while receiving ω3 FA supplementation for 6 months, were analyzed for association to cognitive performance (assessed by ADAS-cog and MMSE scores) as well as to gender. Results: Preservation of cognitive functioning, assessed by ADAS-cog or its sub-items (but not MMSE) scores, was significantly associated to increasing plasma ω3 FA levels over time. Thus, the higher ω3 FA plasma levels rose, the lower was the rate of cognitive deterioration. This effect was not related to gender; since although females displayed higher ω3 FA plasma levels than did males after 6 months of supplementation, this difference disappeared when adjusted for body weight. Conclusions: Since our study suggests dose-response relationships between plasma levels of ω3 FA and preservation of cognition, future ω3 FA trials in patients with mild AD should consider exploring graded (and body weight adjusted) doses of ω3 FA.
    Full-text · Article · Sep 2015 · Journal of Alzheimer's disease: JAD
  • Source
    • "In order to establish reliable lipid diagnostic biomarkers, one needs to dissect the many factors affecting the plasma lipidome which are not necessarily disease-related, e.g., different genetic backgrounds, diet, gender, age, and life style [6] [7] [8] [9] [10] [11]. This creates a severe problem and often plasma lipidomics studies are either performed in a high-throughput manner but targeting only a subset of the lipidome [12] or they cover the whole lipidome for a small sample set [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood plasma has gained protagonism in lipidomics studies due to its availability, uncomplicated collection and preparation, and informative readout of physiological status. At the same time, it is also technically challenging to analyze due to its complex lipid composition affected by many factors, which can hamper the throughput and/or lipidomics coverage. To tackle these issues, we developed a comprehensive, high throughput, and quantitative mass spectrometry-based shotgun lipidomics platform for blood plasma lipid analyses. The main hallmarks of this technology are (i) it is comprehensive, covering 22 quantifiable different lipid classes encompassing more than 200 lipid species; (ii) it is amenable to high-throughput, with less than 5 min acquisition time allowing the complete analysis of 200 plasma samples per day; (iii) it achieves absolute quantification, by inclusion of internal standards for every lipid class measured; (iv) it is highly reproducible, achieving an average coefficient of variation of <10% (intra-day), approx. 10% (inter-day), and approx. 15% (inter-site) for most lipid species; (v) it is easily transferable allowing the direct comparison of data acquired in different sites. Moreover, we thoroughly assessed the influence of blood stabilization with different anticoagulants and freeze-thaw cycles to exclude artifacts generated by sample preparation. Practical applications: This shotgun lipidomics platform can be implemented in different laboratories without compromising reproducibility, allowing multi-site studies and inter-laboratory comparisons. This possibility combined with the high-throughput, broad lipidomic coverage and absolute quantification are important aspects for clinical applications and biomarker research.
    Full-text · Article · Jul 2015 · European Journal of Lipid Science and Technology
  • Source
    • ". Scatter plot of the changes of DHA versus the changes of ADAS-cog during 6 months of 3 FA supplementation, adjusted for baseline ADAS-cog scores, baseline weight, and gender (B = –0.834, p = 0.016). of EPA and DHA in relation to gender in humans and rats [7] [8] [9]. The gender differences have been attributed to sex hormones affecting turnover of these FAs [7]. "

    Full-text · Article · Jul 2014
Show more